Published for Myeloproliferative Neoplasms (MPN)

December 11, 2019

Anthony Messina and Quentin O’Brien presented their abstract and poster at the 61st American Society of Hematology annual conference on Dec 9th. Their work highlighted the frequency at which Patient-Reported Outcome measures are utilized as study endpoints and are made publicly available when clinical trial results are published for Myeloproliferative Neoplasms (MPN). Their in-depth review revealed that a substantial number of the observed MPN randomized trials within their search criteria did not include a PRO measure as a trial endpoint. Of those trials that included a PRO measurement, many lacked the comprehensive reporting needed to inform the assessment of clinical benefit and respective decisions for clinicians and patients, or were published well after the initial trial publication. Their abstract and poster session offered a discussion of the findings and presented recommendations to
improve routine, timely, and appropriate PRO reporting as part of early trial outcome publications.